Çѱ¹¹ÙÀÌ¿ÀÀǾàÇ°Çùȸ ´º½º·¹ÅÍ ±¹¹® Å×½ºÆ®ÆÄÀÏ
|
|
|
º¸µµÀÚ·á |
ÀǾàÇ° ºÎÀÛ¿ë ºÐ¼®À» À§ÇÑ ºòµ¥ÀÌÅÍ ½Ã½ºÅÛ °È
½ÄÇ°ÀǾàÇ°¾ÈÀüó(óÀå ·ù¿µÁø)´Â ½Å·Ú¼º ÀÖ´Â ÀǾàÇ° ¾ÈÀüÁ¤º¸¸¦ È®º¸Çϱâ À§ÇÏ¿© ¡®È¯ÀÚÀüÀÚÀǹ«±â·Ï(EHR, Electronic Health Record)¡¯À» ºÎÀÛ¿ë ºÐ¼® °øÅëµ¥ÀÌÅ͸ðµ¨(CDM, Common Data Model)·Î È°¿ëÇÑ 'ÀǾàÇ° ºÎÀÛ¿ë ºÐ¼® ºòµ¥ÀÌÅÍ ½Ã½ºÅÛ'À» °ÈÇÑ´Ù°í ¹àÇû´Ù.
¿ÃÇØ´Â Áß¾Ó´ë µî 5°³ º´¿ø 20¸¸¸í ȯÀÚ ÀÇ·áÁ¤º¸¸¦ ¡®CDM'À¸·Î ÀüȯÇÏ¿© Ãß°¡ÇÏ°í, ÇâÈÄ `22³â±îÁö Àü±¹ 27°³ Áö¿ªÀǾàÇ°¾ÈÀü¼¾ÅÍ 200¸¸¸í ȯÀÚÀÇ ÀÇ·áÁ¤º¸¸¦ ºòµ¥ÀÌÅÍ·Î ±¸ÃàÇÏ¿© ÀǾàÇ° ºÎÀÛ¿ë ºÐ¼® µî¿¡ È°¿ëÇÒ ¿¹Á¤ÀÌ´Ù.
¡Ø `16³â 4°³º´¿ø(¼¿ï´ë, ÃæºÏ´ë, Ã湫, ³ªÀºº´¿ø), `17³â 5°³º´¿ø(Áß¾Ó´ë, ºÎ»ê´ë, ÀÎÁ¦´ë, º¸¶ó¸Å, °¿ø´ë)
¡®CDM'À» È°¿ëÇÑ ºòµ¥ÀÌÅÍ°¡ ±¸ÃàµÇ¸é ¡ãºÎÀÛ¿ë ¹ß»ý ½Ã ÀǾàÇ°°ú ºÎÀÛ¿ë°£ Àΰú°ü°è¸¦ Á¤È®È÷ ÆľÇÇÒ ¼ö ÀÖÀ» »Ó ¾Æ´Ï¶ó ¡ã¾à¹° º¹¿ë ÈÄ ºÎÀÛ¿ë ¹ß»ý µîÀ» »çÀü¿¡ ¿¹¹æÇÔÀ¸·Î½á ±¹¹Î ¾ÈÀüÀ» È®º¸ÇÏ°í ÀÇ·áºñ¸¦ Àý°¨ÇÒ ¼ö ÀÖ°í, ¡ãÁ¦Ç° °³¹ß¿¡ È°¿ë °¡´ÉÇÑ ÀǾàÇ° ¾ÈÀü¼º Á¤º¸¿Í À¯Åë ÁßÀÎ ÀǾàÇ°ÀÇ ¾ÈÀü¼º Á¤º¸ µîÀ» Á¦°øÇÏ¿© ÀÓ»ó½ÃÇèÀ̳ª À¯Åë ÀǾàÇ° ¾ÈÀü°ü¸® °èȹ ¼ö¸³ ½Ã µµ¿òÀ» ÁÙ ¼ö ÀÖÀ» °ÍÀ¸·Î Àü¸ÁµÈ´Ù......´õ º¸±â |
|
ÀÇ°ßÁ¶È¸ |
¡¸ÀǾàÇ° ÀÓ»ó½ÃÇè ÀÇ·ÚÀÚÀÇ ¾ÈÀü¼º Æò°¡ ¹× º¸°í ½Ã °í·Á»çÇס¹(¾È)¿¡ ´ëÇÑ ÀÇ°ßÁ¶È¸
ÀǾàÇ° ÀÓ»ó½ÃÇèÀÇ Áß´ëÇÏ°í ¿¹»óÄ¡ ¸øÇÑ ¾à¹°ÀÌ»ó¹ÝÀÀº¸°í µî ¾ÈÀü¼º º¸°í¿Í °ü·ÃÇÏ¿©, ÀÓ»ó½ÃÇè ÀÇ·ÚÀÚ°¡ °ü·Ã ¾ÈÀü¼º Á¤º¸¸¦ Æò°¡ÇÏ°í º¸°íÇÔ¿¡ ÀÖ¾î °í·ÁÇØ¾ß ÇÒ »çÇ× µîÀ» Á¦°øÇϱâ À§ÇØ ¡¸ÀǾàÇ° ÀÓ»ó½ÃÇè ÀÇ·ÚÀÚÀÇ ¾ÈÀü¼º Æò°¡ ¹× º¸°í ½Ã °í·Á»çÇס¹(¹Î¿øÀξȳ»¼)À» ¸¶·ÃÇÏ°íÀÚ ÇÔ
¡Û ÀǾàÇ° ÀÓ»ó½ÃÇè ÀÇ·ÚÀÚÀÇ ¾ÈÀü¼º Æò°¡ ¹× º¸°í ½Ã °í·Á»çÇ× (Á¦Á¤¾È)
¡Û ÀÇ°ß Á¦Ãâ ¸¶°¨ÀϽà : ~ 7 / 27ÀÏ (¸ñ)
¡Û ÀÇ°ß Á¦Ãâó : info@kobia.kr
|
|
|
ÀÇ°ßÁ¶È¸ |
¡¸µ¿µî»ý¹°ÀǾàÇ°(¹ÙÀÌ¿À½Ã¹Ð·¯) Çã°¡»çÇ× °ü¸®¹æ¾È¡¹ÀÇ°ßÁ¶È¸
µ¿µî»ý¹°ÀǾàÇ°(¹ÙÀÌ¿À½Ã¹Ð·¯)(ÀÌÇÏ ¹ÙÀÌ¿À½Ã¹Ð·¯) Ç°¸ñÇã°¡ ÈÄ ´ëÁ¶¾àÀÇ Çã°¡»çÇ× º¯°æ¿¡ µû¶ó ´ëÁ¶¾à°ú ¹ÙÀÌ¿À½Ã¹Ð·¯ °£ Çã°¡»çÇ× Â÷ÀÌ ¹ß»ýÇÏ¿©, ´ëÁ¶¾à Çã°¡»çÇ× º¯°æ µî¿¡ µû¸¥ ¹ÙÀÌ¿À½Ã¹Ð·¯ÀÇ Çã°¡ »çÇ× °ü¸® ±âÁØ ¸¶·Ã ÇÊ¿ä
¹ÙÀÌ¿ÀÀǾàÇ°ÀÇ ÀüÁÖ±â Çã°¡°ü¸®ÀÇ ÀÏȯÀ¸·Î ¸¶·ÃÇÑ ¡¸µ¿µî»ý¹°ÀǾàÇ°(¹ÙÀÌ¿À½Ã¹Ð·¯) Çã°¡»çÇ× °ü¸®¹æ¾È¡¹(¾È)¿¡ ´ëÇØ ÀÇ°ßÀ» Á¶È¸ÇÏ°íÀÚ ÇÔ
¡Û µ¿µî»ý¹°ÀǾàÇ°(¹ÙÀÌ¿À½Ã¹Ð·¯) Çã°¡»çÇ× °ü¸®¹æ¾È
¡Û ÀÇ°ß Á¦Ãâ ¸¶°¨ÀϽà : ~ 7 / 26ÀÏ (¼ö)
¡Û ÀÇ°ß Á¦Ãâó : info@kobia.kr
|
|
°øÁö |
¹ÙÀÌ¿ÀÀǾàÇ° µî Çã°¡½É»ç´Ü°è °ø½Ä¹Î¿øȸÀÇ ´ë»ó È®´ë
¤· °ø½Ä¹Î¿øȸÀÇ °³¿ä
- ´ë»ó : ¹ÙÀÌ¿ÀÀǾàÇ°, ÇѾà(»ý¾à)Á¦Á¦ÀÇ ½Å¾à ¹× ½Å±Ô Çã°¡½Åû ¹Î¿ø
- °³ÃÖ½Ã±â ¹× ÁÖ¿ä³»¿ë
¡¤ º¸¿Ï ÈÄ(D80) ¹Î¿øȸÀÇ : Á¦ÃâÀÚ·á °ËÅäÀÇ°ß, º¸¿Ï»çÇ×, ÀÚ¹®È¸ÀÇ °³ÃÖ ¿©ºÎ µî ¼³¸í
¡¤ Çã°¡ Àü(D100) ¹Î¿øȸÀÇ : ÁÖ¿ä Çã°¡»çÇ×(¾È) ¹× Çã°¡Á¶°Ç ³íÀÇ
- ¹æ¹ý : ´ë¸é ¶Ç´Â È»óȸÀÇ
¤· °ø½Ä¹Î¿øȸÀÇ ´ë»ó È®´ë
- È®´ë¹üÀ§ : ¾ÈÀü¼ºÀ¯È¿¼º½É»ç(È¿´ÉÈ¿°ú, ¿ë¹ý¿ë·®º¯°æ)¸¦ Æ÷ÇÔÇÑ Ç°¸ñº¯°æÇã°¡
- °³Ãֽñâ : º¸¿Ï ÈÄ(D45), Çã°¡ Àü(D55)¿¡ °³ÃÖ
- È®´ë ½ÃÇà½Ã±â : 2017.7.19. ÀÌÈÄ Á¢¼öµÈ ¹Î¿øºÎÅÍ È®´ë ½ÃÇà
½ÃÇà¾È³»¹® È®ÀÎ |
|
ÀÚ·á |
¢º ½ÄÇ°¡¤ÀǾàÇ°ºÐ¾ß ½ÃÇ衤°Ë»ç±â°ü Æò°¡¿¡ °üÇÑ ±ÔÁ¤ ÀϺΰ³Á¤°í½Ã
¢º 2017³â ½ÄÇ°ÀǾàÇ°¾ÈÀü¹é¼ ¹Ù·Î°¡±â |
|
|
|
|
º¹ÁöºÎ |
2017³â Å©·Î¾ÆƼ¾Æ ¹Î°üÇÕµ¿ º¸°ÇÀÇ·áÇù·Â »çÀý´Ü ÆÄ°ß ¼ö¿äÁ¶»ç
¡à º¸°Çº¹ÁöºÎ¿¡¼´Â º¸°ÇÀÇ·á ¹× ¿¬°ü »ç¾÷ÀÇ ÇØ¿Ü ÁøÃâÀ» Áö¿øÇϱâ À§ÇÏ¿© ¿Ü±³ºÎ Àç¿Ü°ø°ü°úÀÇ Çù·Â »ç¾÷À¸·Î '¸ÞµðÄÃÄÚ¸®¾Æ °ÅÁ¡°ø°ü »ç¾÷*'À» ½Ç½ÃÇÏ°í ÀÖÀ¸¸ç, 2017³â ¸ÞµðÄÃÄÚ¸®¾Æ °ÅÁ¡°ø°ü »ç¾÷À¸·Î ¼±Á¤µÈ ÁÖ Å©·Î¾ÆƼ¾Æ´ëÇѹα¹´ë»ç°ü°ú Çù·ÂÇÏ¿© 'Å©·Î¾ÆƼ¾Æ ¹Î°ü ÇÕµ¿ º¸°ÇÀÇ·áÇù·Â »çÀý´Ü'ÆÄ°ßÀ» ÃßÁøÇÏ°íÀÚ ÇÔ
¤· [Å©·Î¾ÆƼ¾Æ º¸°ÇÀÇ·áÇù·Â»çÀý´Ü ÆÄ°ß°³¿ä]
- ÀÏÁ¤ : 2017³â 10¿ù¸», 3¹Ú4ÀÏ (ÀáÁ¤¾È) *»çÀý´Ü ÆÄ°ß ¿©ºÎ¿¡ µû¶ó Çà»ç °³ÃÖ ÀÏÁ¤ º¯°æ°¡´É
- ¹æ¹®±¹°¡ : Å©·Î¾ÆƼ¾Æ(ÀÚ±×·¹ºê)
- ÁÖ¿äÈ°µ¿ : ¾ç±¹ º¸°ÇºÎ°£ º¸°ÇÇù·Â MOU ü°á, Á¤ºÎ ÁÖ¿äÀÎ»ç ¸é´ã, ÇöÀå½ÃÂû, 1:1 ºñÁî´Ï½º »ó´ãȸ, ÇÑ-Å©·Î¾ÆƼ¾Æ Á¦¾à ÀÇ·á±â±â ¼¼¹Ì³ª °³ÃÖ µî
»çÀý´Ü Âü¿©¸¦ Èñ¸ÁÇÏ´Â ±â°ü ¹× ¾÷ü¿¡¼´Â ¼½ÄÀ» È®ÀÎÇϽðí ~17.7.27(¸ñ)±îÁö ´ã´çÀÚ¿¡°Ô Á¦ÃâÇÏ¿© Áֽñ⠹ٶø´Ï´Ù.......´õ º¸±â
- inae.kim@kobia.kr
- ¹®ÀÇ : 02-725-8432
|
|
½ÉÆò¿ø |
¡®¾àÁ¦°ü¸®Á¦µµ°³¼±ÆÀ¡¯ ½Å¼³ ¿î¿µ
¡à °Ç°º¸Çè½É»çÆò°¡¿ø(¿øÀå ±è½ÂÅÃ, ÀÌÇÏ ¡®½É»çÆò°¡¿ø¡¯)Àº »õ Á¤ºÎ º¸°ÇÀÇ·áÁ¤Ã¥ ¹æÇâ¿¡ ºÎÇÕÇÏ´Â ¾àÁ¦°ü¸® ¹æ¾ÈÀ» ¸¶·ÃÇϱâ À§ÇØ ¡®¾àÁ¦°ü¸® Á¦µµ°³¼±ÆÀ¡¯(ÀÌÇÏ ¡®Á¦µµ°³¼±ÆÀ¡¯)À» ¿î¿µÇÑ´Ù.
¡Û ¾àÁ¦°ü¸®½Ç ³»¿¡ ½Å¼³µÈ Á¦µµ°³¼±ÆÀÀº ¾àÁ¦°ü¸® ½Ç¹« °æÇèÀÌ Ç³ºÎÇÑ ¿¬±¸¿ø ¹× ¾à»ç 10¸íÀ» ½Ç³» Á¶Á¤ÇÏ¿© ¹èÄ¡․¿î¿µÇϸç, Áö³ 7¿ù 14ÀÏ º¸°Çº¹ÁöºÎ¿Í ÇÕµ¿ Kick-off ȸÀǸ¦ °®´Â µî ¾÷¹«¸¦ ½ÃÀÛÇß´Ù.
¡Û ÁÖ¿ä ¾÷¹«
¡ã°í°¡ ½Å¾àÀÇ ½Å¼Ó µîÀç ¡ã±âµîÀç °í°¡¾àÁ¦ »çÈÄ°ü¸® ¡ã¸¸¼ºÁúȯ ¾àÇ°ºñ °ü¸® ¡ãÇã°¡ ÃÊ°ú ¾àÁ¦°ü¸® µî¿¡ °üÇÑ ±¸Ã¼ÀûÀÎ °³¼± ¹æ¾È µî......º¸µµÀÚ·á º¸±â
|
|
|
|
|
|
½ÅûÀÚ |
½ÂÀÎÀÏ |
Á¦Ç°¸í |
ÀÓ»ó |
´Ü°è |
Çѹ̾àÇ°(ÁÖ) |
20170720 |
µµ¼¼Å¹¼¿°ú ½ÃŬ·ÎÆ÷½ºÆĸ¶À̵å(TC)¸¦ Åõ¿©ÇÑ Ãʱâ À¯¹æ¾Ï ȯÀÚ¸¦ ´ë»óÀ¸·Î Ç×¾ÏÈÇпä¹ýÀ¸·Î À¯µµµÈ È£Áß±¸ °¨¼ÒÁõ Ä¡·á¿¡ ÀÖ¾î Æä±×Çʱ׶ó½ºÆÀ(Pegfilgrastim) ´ëºñ SPI-2012 (¿¡ÇöóÆä±×¶ó½ºÆÀ, Eflapegrastim)ÀÇ ¹«ÀÛÀ§ ¹èÁ¤, °ø°³, È°¼º ´ëÁ¶ ÀÓ»ó½ÃÇè(RECOVER)
|
3»ó |
HM10460A |
|
|
|
|
|
|
|
|
FDA |
|
Drug Name and
FDA Appl. # |
Active Ingredients |
Submission
Classification |
Company |
Approval Date |
VOSEVI
NDA #209195 |
SOFOSBUVIR;
VELPATASVIR
VOXILAPREVIR |
½Å¹°Áú/½Åº¹ÇÕ |
GILEAD SCIENCES INC |
07/18/2017 |
LUSDUNA
NDA #208722 |
INSULIN GLARGINE |
½ÅÁ¦Çü ¶Ç´Â ½ÅÁ¦Á¶¿ø |
MERCK SHARP DOHME |
07/19/2017 |
|
|
|
|
EMA |
|
Name |
Active Substance |
Therapeutic areaCompany |
Date of authorisation/ refusal |
Spherox |
spheroids of human autologous matrix-associated chondrocytes |
Cartilage Diseases |
10/07/2017 |
|
|
|
|
PMDA |
|
Name |
Active Substance |
Therapeutic areaCompany |
Date of authorisation/ refusal |
Parmodia? tablets 0.1 mg |
Kowa Corporation |
Pemafibrate |
2017.07.03 |
Olumiant tablets 4 mg
¡¡ÔÒ tablets 2 mg |
Japan Eli Lilly Co., Ltd., |
Baricitinib |
2017.07.03 |
Amenalief? tablets 200 mg |
Maruho Corporation |
Amenamevir |
2017.07.03 |
CANALIA? Combination Tablets |
Mitsubishi Tanabe Pharma Corporation |
Teneligliptin / Canagliflozin |
2017.07.03 |
Bipresso sustained release tablet 50 mg
ÔÒ sustained release tablets 150 mg |
Astellas Pharma Inc., |
Quetiapine fumarate |
2017.07.03 |
Difolta? injection 20 mg |
Mundipharma Corporation, |
Pralatrexate |
2017.07.03 |
Istodax? for intravenous infusion 10 mg |
Celgene Co., Ltd., |
Romidepsin |
2017.07.03 |
Spinraza intrathecal injection 12 mg |
Biogen Japan Co., Ltd., |
Nusinersen sodium |
2017.07.03 |
Jadenu granule 90 mg
ÔÒ granule 360 mg |
Novartis Pharma Corporation, |
Deferasirox |
2017.07.03 |
|
|
|
|
|
|
|
Clinical.gov ¹Ì±¹ |
NCT
Number |
Title |
Conditions |
Interventions |
Sponsor
/Collaborators |
Phases |
NCT03223610 |
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma |
Lymphoma
Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Burkitt Lymphoma |
Drug: Venetoclax
Drug: Ibrutinib
Drug: Prednisone
Drug: Obinutuzumab
Drug: Revlimid (lenalidomide) |
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC) |
Phase 1 |
NCT03223103 |
Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma |
Glioblastoma |
Drug: Poly-ICLC
Device: Tumor Treating Fields
Biological: Peptides |
Adilia M Hormigo
NovoCure Ltd.
Icahn School of Medicine at Mount Sinai |
Phase 1 |
NCT03226249 |
PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma |
Classical Hodgkin Lymphoma
Lymphocyte-Depleted Classical Hodgkin Lymphoma
Lymphocyte-Rich Classical Hodgkin Lymphoma
Mixed Cellularity Classical Hodgkin Lymphoma
Nodular Sclerosis Classical Hodgkin Lymphoma |
Procedure: Computed Tomography
Drug: Dacarbazine
Drug: Doxorubicin Hydrochloride
Radiation: Fludeoxyglucose F-18
Other: Laboratory Biomarker Analysis
Biological: Pembrolizumab
Procedure: Positron Emission Tomography
Drug: Vinblastine Sulfate |
Northwestern University
National Cancer Institute (NCI) |
Phase 2 |
|
|
Clinical.gov À¯·´ |
NCT
Number |
Title |
Conditions |
Interventions |
Sponsor
/Collaborators |
Phases |
Nation |
NCT03227263 |
BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia (HHT). A National, Multicenter Phase III Study |
Hemorrhagic Hereditary Telangiectasia (HHT) |
Drug: Bevacizumab
Drug: sodium chloride 0.9% |
Hospices Civils de Lyon |
Phase 3 |
ÇÁ¶û½º |
NCT03225924 |
Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by Chemiotherapy |
DLBCL |
Drug: Entospletinib
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone |
The Lymphoma Academic Research Organisation |
Phase 1
Phase 2 |
ÇÁ¶û½º |
|
|
|
|
|
|
|
¹ÙÀÌ¿ÀITÇ÷§Æû '17³â ½Å±ÔÁ¦°øÁ¤º¸ ¾È³» |
¹ÙÀÌ¿ÀITÇ÷§ÆûÀÇ 2017³â ½Å±Ô Á¦°ø Á¤º¸ |
2017³âµµ¿¡´Â Áö³ ÇØ ±ÔÁ¦¡¤»ê¾÷Á¤º¸¸¦ Á¦°øÇÏ¿´´ø 12°³±¹ ¿Ü¿¡ º£Æ®³², Àεµ³×½Ã¾Æ, ÆÄÅ°½ºÅºÀÇ 3°³±¹ Á¤º¸¸¦ Ãß°¡·Î Á¦°øÇÒ ¿¹Á¤ÀÔ´Ï´Ù. ¸¹Àº °ü½É°ú ÀÌ¿ëÀ» ºÎŹ µå¸³´Ï´Ù. |
|
¹ÙÀÌ¿ÀITÇ÷§Æû Àü¹®ÄÁ¼³Æà ¾È³» |
2017³â¿¡´Â ÁÖ¿ä ±Ç¿ª(¹Ì±¹, À¯·´, Áß±¹)º° Àü¹® ÄÁ¼³Æà ¾÷üÀÇ ÀÎÇã°¡ Á¾ÇÕ Áö¿ø ¼ºñ½º(2017 ÷´Ü¹ÙÀÌ¿ÀÀǾàÇ° ÇØ¿ÜÁøÃâ Á¾ÇÕÁö¿ø »ç¾÷ ¡º¹ÙÀÌ¿ÀITÇ÷§Æû¡» Àü¹®ÄÁ¼³ÆÃ)¸¦ »õ·Ó°Ô ½Ç½ÃÇÒ ¿¹Á¤ÀÔ´Ï´Ù. ¸¹Àº ½Åû ¹Ù¶ø´Ï´Ù. |
'Àü¹®ÄÁ¼³ÆÃ' À̶õ? |
¹ÙÀÌ¿ÀÀǾàÇ° ÇØ¿Ü ÀÎÇã°¡ °ü·Ã ¾÷¹«°æÇèÀÌ ÀÖ´Â Àü¹® ÄÁ¼³Æà ±â°üÀÇ
1:1(ÄÁ¼³Æñâ°ü:ÄÁ¼³Æà ÀÇ·Ú ¾÷ü) ÄÁ¼³Æà |
|
|
Èñ¸ÁÇϽô ¾÷ü²²¼´Â Çùȸ ¶Ç´Â ¹ÙÀÌ¿ÀITÇ÷§Æû ȨÆäÀÌÁöÀÇ ¡®¹ÙÀÌ¿ÀITÇ÷§Æû Àü¹®ÄÁ¼³Æà ½Åû¡¤Á¢¼ö °ø°í¡¯¸¦ È®ÀÎÇϽðí,
¡®¹ÙÀÌ¿ÀÀǾàÇ° ÇØ¿ÜÁøÃâ Àü¹®ÄÁ¼³Æà ÀÇ·Ú¼¡¯¸¦ ÀÛ¼ºÇϽþî À̸ÞÀÏ(bpis@kobia.kr) ½Åû¡¤Á¢¼öÇϽñ⠹ٶø´Ï´Ù.
µ¿ÀÏ ±â¾÷Àº ÃÖ´ë 5°Ç±îÁö ½ÉÈ, ¿¬°è ÄÁ¼³ÆÃ(´Ü°èº°) ÀÇ·Ú°¡ °¡´ÉÇÕ´Ï´Ù. |
|
¢º ¹ÙÀÌ¿ÀITÇ÷§Æû Àü¹®ÄÁ¼³Æà °ø°í (»ó½ÃÁ¢¼ö) ¹Ù·Î°¡±â |
|
¢º ¹ÙÀÌ¿ÀITÇ÷§Æû ¹Ù·Î°¡±â |
|
|
|
|
|
|
|
|
Àü½ÃºÎ½º Âü°¡¿¡ °ü½ÉÀÖÀ¸½Å ºÐµéÀº Çùȸ·Î ¿¬¶ô ºÎŹµå¸³´Ï´Ù. ÀÌ¿¬Á¤ (02-725-8438 / yjlee@kobia.kr) |
|
|
|
|
|
|
|
|